Ignota Labs Limited
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Dec 2034
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 9, 2027The maintenance fee for SUBSTITUTED IMIDAZO[1,2-a]PYRAZINES AS SYK INHIBITORS (US 10,342,794) comes due Jan 9, 2027. Unpaid by Jul 9, 2027, it lapses early.
- 1 fee due Sep 22, 2027The maintenance fee for SUBSTITUTED IMIDAZO[1,2-a]PYRAZINES AS SYK INHIBITORS (US 9,290,505) comes due Sep 22, 2027. Unpaid by Mar 22, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,290,505 | SUBSTITUTED IMIDAZO[1,2-a]PYRAZINES AS SYK INHIBITORS In force · High confidence | In force | High confidence | |
| US 9,968,601 | SUBSTITUTED IMIDAZO[1,2-a]PYRAZINES AS SYK INHIBITORS In force · Medium confidence | In force | Medium confidence | |
| US 10,342,794 | SUBSTITUTED IMIDAZO[1,2-a]PYRAZINES AS SYK INHIBITORS In force · High confidence | In force | High confidence | |
| US 10,828,299 | CRYSTALLINE MONOMESYLATE SALT OF 6-(6-Aminopyrazin-2-YL)-N-(4-(4-(OXETAN-3-YL)PIPERAZIN-1-YL)PHENYL)IMIDAZO[1,2-a]PYRAZIN-8-Amine In force · High confidence | In force | High confidence | |
| US 12,263,163 | CRYSTALLINE SUCCINATE SALT OF 6-(6-Aminopyrazin-2-YL)-N-(4-(4-(OXETAN-3-YL)PIPERAZIN-1-YL)PHENYL)IMIDAZO[1,2-a]PYRAZIN-8-Amine AS A SYK INHIBITOR In force · High confidence | In force | High confidence | |
| US 11,517,570 | CRYSTALLINE SUCCINATE SALT OF 6-(6-Aminopyrazin-2-YL)-N-(4-(4-(OXETAN-3-YL)PIPERAZIN-1-YL)PHENYL)IMIDAZO[1,2-a]PYRAZIN-8-Amine In force · High confidence | In force | High confidence | |
| US 9,931,338 | Syk Inhibitors In force · High confidence | In force | High confidence | |
| US 10,111,882 | Syk Inhibitors In force · High confidence | In force | High confidence | |
| US 11,155,560 | Substituted pyrazolo[1,5-a]pyrimidines for modulating CDK9 activity In force · From the USPTO record | In force | From the USPTO record | |
| US 12,152,037 | CRYSTALLINE SUCCINATE SALT OF 6-(6-Aminopyrazin-2-YL)-N-(4-(4-(OXETAN-3-YL)PIPERAZIN-1-YL)PHENYL)IMIDAZO[1,2-a]PYRAZIN-8-Amine AS A SYK INHIBITOR In force · High confidence | In force | High confidence |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.